Apr 01, 2026-
Beam Therapeutics has announced the publication of interim data from its Phase 1/2 BEACON clinical trial evaluating ristoglogene autogetemcel (risto-cel, formerly BEAM-101) for the treatment of sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs) in The New England Journal of Medicine. The publication highlights promising safety and efficacy results and reinforces the potential of risto-cel as a differentiated gene-edited cell therapy for SCD.
Risto-cel is an autologous hematopoietic stem cell therapy developed using base editing technology that avoids viral vectors, a precise gene editing approach designed to modify DNA without introducing double-strand breaks.
The therapy works by editing the promoter regions of the HBG1 and HBG2 genes to increase the production of fetal hemoglobin (HbF)—a non-sickling form of hemoglobin that can compensate for the defective adult hemoglobin responsible for disease pathology.
Data published in NEJM included 31 patients with SCD and severe VOCs treated in the BEACON Phase 1/2 trial. Follow-up ranged from 0.3 to 20.4 months as of the August 2025 data cutoff. The results demonstrated rapid and robust clinical responses following treatment. Patients achieved mean fetal hemoglobin levels above 60%, while levels of sickle hemoglobin (HbS) decreased to below 40%, creating a protective hemoglobin ratio similar to individuals with sickle cell trait.
Importantly, no patients experienced investigator-reported severe vaso-occlusive crises following engraftment, and all patients experienced resolution of anemia after elimination of transfused blood. Markers of hemolysis improved or normalized across patients, indicating a broad correction of red blood cell dysfunction.
Operational metrics from the trial also demonstrated encouraging efficiency. Patients required a median of only one stem cell collection cycle to generate the therapy. The median time from cell collection to drug product release was 2.9 months, while the median time from collection to dosing was 4.5 months. Following transplantation, patients experienced rapid bone marrow engraftment, supporting the feasibility of the treatment process across multiple clinical centers.
The therapy’s safety profile was reported to be consistent with standard myeloablative conditioning using busulfan and autologous hematopoietic stem cell transplantation, along with safety considerations related to underlying SCD.
Beam Therapeutics believes these results support risto-cel’s potential best-in-class profile among emerging gene and cell therapies for SCD. The company is currently working toward a Biologics License Application (BLA) submission expected as early as the end of 2026.
The adult and adolescent cohorts of the BEACON trial were fully enrolled in mid-2025, and manufacturing of all doses was completed by December 2025. The therapy has received FDA Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation, and it has also been accepted into the FDA’s CMC Development and Readiness Pilot (CDRP) program, which aims to accelerate manufacturing readiness for advanced therapies.
Sickle cell disease remains the most common inherited blood disorder in the United States, affecting approximately 100,000 individuals in the U.S. and about eight million people worldwide. The disease is caused by a single mutation in the beta-globin gene, leading to the production of sickle hemoglobin (HbS), which distorts red blood cells into a rigid shape that blocks blood vessels and causes severe pain crises, anemia, organ damage, and reduced life expectancy.
By leveraging precision base editing to reactivate fetal hemoglobin production, risto-cel aims to replicate a naturally occurring protective condition known as hereditary persistence of fetal hemoglobin, offering a potentially durable, one-time treatment for patients with severe SCD.
